Overview

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to characterize the pharmacokinetic properties of maraviroc alone and when administered with rifabutin and to assess rifabutin and 25-O-desacetyl-rifabutin pharmacokinetics compared to the literature.
Phase:
Phase 1
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborator:
Pfizer
Treatments:
Maraviroc
Rifabutin